Skip to main content
SpringerLink
Log in

Insulin analogues and management of diabetes mellitus

  • Symposium: Pediatric Endocrinology — II
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

The introduction of insulin analogues, of which insulin lispro is the prototype, marks a very important milestone in the management of patients with diabetes mellitus. It differs from regular human insulin in its quicker onset and shorter duration of action. Invarious clinical trials, insulin lispro was found to be superior to regular human insulin in controlling postprandial hyperglycemia without increasing the risk of hypoglycemia. It improved the quality of life of diabetic patients by providing more flexibility to meal plans. Recently, another short acting insulin analogue called insulin aspart has been tried in clinical studies with benefits similar to insulin lispro. The turn of the millennium is now witnessing the development of long acting insulin analogues like insulin glargine, which can provide continuous low-level basal insulin concentrations similar to natural settings. In this review, we discuss the potential of insulin analogues in the modern management of diabetes with emphasis on insulin lispro.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus.N Engl J Med 1993; 329: 977–86.

    Article  Google Scholar 

  2. Holleman F, Hoekstra JBL. Insulin lispro.N Engl J Med 1997; 337: 176–83.

    Article  PubMed  CAS  Google Scholar 

  3. Campbell RK, Campbell LK, White JR. Insulin lispro: Its role in the treatment of diabetes mellitus.Ann Pharmacol 1996; 30: 1263–70.

    CAS  Google Scholar 

  4. Grossman LD. New insights into the clinical benefits of insulin lispro.Can J Diabetes Care 1998; 22: 34–8.

    Google Scholar 

  5. Mudaliar SR, Linberg FA, Joyce M,et al. Insulin aspart (B28 asp-insulin): A fast acting analog of human insulin Absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.Diabetes Care 1999; 22: 1501–6.

    Article  PubMed  CAS  Google Scholar 

  6. Bolli GB. Rationale for using combinations of short acting insulin analogue and NPH insulin at mealtime in the treatment of type 1 diabetes mellitus.J Pediatr Endocrinol Metab 1999; 12: 737–44.

    PubMed  Google Scholar 

  7. Sheker LJ, Sundell K. Modification in the 28–29 position of insulin B chain after binding to the IGF-1 receptor with minimal effect on insulin receptor binding.Diabetes 1991; 40 (suppl 1): 1684.

    Google Scholar 

  8. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. Lys (B28) Pro (B29)- human insulin. A rapidly absorbed analog of human insulin.Diabetes 1994; 43: 396–402.

    Article  PubMed  CAS  Google Scholar 

  9. Holleman F, van den Brand JJG, Horen RARAet al. Comparison of Lys B28, Pro B29 human insulin analog and regular insulin in the correction of incidental hyperglycemia.Diabetes Care 1996; 19: 1426–9.

    Article  PubMed  CAS  Google Scholar 

  10. Woodworth J, Howey D, Bowsher R, Lutz S, Santa P, Brady P. Lys B28 Pro B29 human insulin (k). Dose ranging versus Humulin R..Diabetes 1993; 42 (suppl. 1): 54A (abstract).

    Google Scholar 

  11. Ling J, Hu M, Hagerup T, Campbell RK. Lispro insulin: Adsorption and stability in selected intravenous devices.Diabetes Edu 1999; 25: 237–45.

    Article  CAS  Google Scholar 

  12. Anderson JH, Brunelle RL, Kovinisto VAet al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin analogue treatment.Diabetes 1997; 46: 265–70.

    Article  PubMed  CAS  Google Scholar 

  13. Holleman F, Schmutt H, Rottiers R, Rees A, Symanowski S, Anderson JH. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro.Diabetes Care 1998; 20: 1827–32.

    Article  Google Scholar 

  14. Wilde MI, McTavish D. Insulin lispro: A review of its pharmacological properties and therapeutic use in the management of diabetes mellitus.Drugs 1997; 54: 597–614.

    Article  PubMed  CAS  Google Scholar 

  15. Davey P, Grainger D, Macmillan J, Rajan N, Aristides M, Gliksman M. Clinical outcomes with insulin lispro compared with human regular insulin: A metaanalysis.Clin Ther 1997; 19: 656–74.

    Article  PubMed  CAS  Google Scholar 

  16. Puttagunta AL, Toth EL. Insulin lispro (Humalog), the first marketed insulin analogue: Indications, contraindications and need for further study.CMAJ 1998; 158: 506–11.

    PubMed  CAS  Google Scholar 

  17. Holcombe J, Zalani S, Arora V, Headlee S, Gill A. Insulin lispro results in less nocturnal hypoglycemia compared with regular insulin in adolescents with type 1 diabetes.Diabetes 1997; 46 (suppl 1): 103A.

    Google Scholar 

  18. Heller SR, Amiel SA, Mansell P. Effect of fast acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group.Diabetes Care 1999; 22: 1607–11.

    Article  PubMed  CAS  Google Scholar 

  19. Heller SR, Amiel SA, Janes J. Hypoglycemia during intensive insulin therapy: A comparison of lispro and regular insulin.Diabetes 1997; 46 (suppl 1): 151A.

    Google Scholar 

  20. Ahmed AB, Home PD. The effect of the insulin analog lispro on night time blood glucose control in type 1 diabetic patients.Diabetes Care 1998; 21: 32–7.

    Article  PubMed  CAS  Google Scholar 

  21. Brunelle BL, Llewelyn J, Anderson JH, Gale EA, Koivisto VA. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes.Diabetes Care 1998; 21: 1726–31.

    Article  PubMed  CAS  Google Scholar 

  22. Heinemann L. Hypoglycemia and insulin analogues: Is there a reduction in the incidence?J Diabetes Complications 1999; 13: 105–14.

    Article  PubMed  CAS  Google Scholar 

  23. Berger M, Heinemann L. Are the presently available insulin analogues clinically beneficial?Diabetologia 1997; 40: 1–96.

    Article  Google Scholar 

  24. Lalli C, Ciofetta M, del Sindaco Pet al. Long term intensive treatment of type 1 diabetes with short-acting insulin analog lispro in variable combination with NPH insulin at mealtime.Diabetes Care 1999; 22: 468–77.

    Article  PubMed  CAS  Google Scholar 

  25. Vignati L, Anderson JH, Iverson PW. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin dependent or non-insulin dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.Clin Ther 1997; 19: 1408–21.

    Article  PubMed  CAS  Google Scholar 

  26. Bolli GB, DiMarchi RD, Park G, Pramming S, Koivisto VA. Insulin analogs and their potential in management of diabetes mellitus.Diabetologia 1999; 42: 1151–67.

    Article  PubMed  CAS  Google Scholar 

  27. Ronnemaa T, Vikari J. Reduction of snacks when switching from conventional soluble to lispro insulin. Effects on glycemic control and hypoglycemia.Diabetic Med 1998; 15: 601–7.

    Article  PubMed  CAS  Google Scholar 

  28. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack TR. Insulin lispro in continuous subcutaneous insulin infusion. Results of a double blind crossover study.Diabetes 1997; 46: 440–3.

    Article  PubMed  CAS  Google Scholar 

  29. Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.Diabetes Care 1999; 22: 784–8.

    Article  PubMed  CAS  Google Scholar 

  30. Pein M, Hinselmann C, Pfutzner A, Dreyer M. Catheter disconnection in type 1 diabetic patients treated with CSII. Comparison of insulin lispro and human regular insulin.Diabetologia 1996; 36 (suppl 1): A223 (abstract).

    Google Scholar 

  31. Attia N, Jones TW, Holcombe J, Tamborlane WV. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.Diabetes Care 1998; 21: 817–21.

    Article  PubMed  CAS  Google Scholar 

  32. Jacobs MAJM, Salobir B, Aarsen M, van Iperen A, Heine RJ. Hypoglycemic thresholds for glucose counterregulatory responses to LysB28 ProB29 human insulin analog.Horm Metab Res 1994; 26 (suppl): A34 (abstract).

    Google Scholar 

  33. Schernthaner G, Wein W, Sandholzer K, Equiluz-Bruck S, Bates PC, Birkett MA. Postprandial insulin lispro: A new therapeutic option for type 1 diabetic patients.Diabetes Care 1998; 21: 570–3.

    Article  PubMed  CAS  Google Scholar 

  34. Kotsanos JG, Vignati L, Huster W. Health related quality of life results from multinational clinical trials of insulin lispro.Diabetes Care 1997; 20: 948–58.

    Article  PubMed  CAS  Google Scholar 

  35. Tubiana-Rufi N, Munz-Licha G. Lispro analog and quality of life.Diabetes Metab 1997; 23 (suppl 3): 58–62.

    PubMed  Google Scholar 

  36. Lahtela JT, Knip M, Paul R, Antonen J, Salmi J. Severe insulin antibody mediated human insulin resistance: Successful treatment with insulin analog lispro.Diabetes Care 1997; 20: 71–3.

    Article  PubMed  CAS  Google Scholar 

  37. Travaglini MT, Garg SK, Chase HP. Use of insulin lispro in the outpatient management of ketonuria.Arch Pediatr Adolesc Med 1998; 152: 672–5.

    PubMed  CAS  Google Scholar 

  38. Jovanovic L, Ilic S, Pettitt DJet al. Metabolic and immunologic effects of insulin lispro in gestational diabetes.Diabetes Care 1999; 22: 1422–7.

    Article  PubMed  CAS  Google Scholar 

  39. Rutledge KS, Chase HP, Klingensmith GJ, Walravens PA, Slover RH, Garg SK. Effectiveness of postprandial Humalog in toddlers with diabetes.Pediatrics 1997; 100: 968–72.

    Article  PubMed  CAS  Google Scholar 

  40. Rami B, Schober E. Postprandial glycaemia after regular and lispro insulin in children and adolescents with diabetes.Eur J Pediatr 1997; 156: 838–40.

    Article  PubMed  CAS  Google Scholar 

  41. Roper NA, Bilous RW. Resolution of lipohypertrophy following change of short acting insulin to insulin lispro (Humalog).Diabetes Med 1998; 15: 1063–4.

    Article  CAS  Google Scholar 

  42. Caixas A, Perez A, Payes Aet al. Effects of a short acting insulin analog (Insulin lispro) versus regular insulin on lipid metabolism in insulin dependent diabetes mellitus.Metabolism 1998; 47: 371–6.

    Article  PubMed  CAS  Google Scholar 

  43. Ish-Shalom D, Christofferson CT, Vorwerk Pet al. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor.Diabetologia 1997; 40: S25-S31.

    Article  PubMed  CAS  Google Scholar 

  44. Srachnan MW, Frier BM. Optimal time of administration of insulin lispro. Importance of meal composition.Diabetes Care 1998; 21: 26–31.

    Article  Google Scholar 

  45. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: A multicenter randomized double blind crossover trial in type 1 diabetic patients. U.K. Insulin Aspart Study Group.Diabetes Care 1998; 21: 1904–9.

    Article  PubMed  CAS  Google Scholar 

  46. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomised double blind crossover trial in type 1 diabetes.Diabetes Care 1999; 22: 801–5.

    Article  PubMed  CAS  Google Scholar 

  47. Pieber T. Long acting insulin analogues: Can they provide a basal insulin level?J Pediatr Endocrinol Metab 1999; 12: 745–50.

    PubMed  Google Scholar 

  48. Pieber T, Eugene-Jolchine I, Derobet E. Efficacy and safety of HOE 901 in patients with type 1 diabetes: A four week randomised, NPH insulin controlled trial.Diabetes 1998; 47: A63 (abstract).

    Google Scholar 

  49. Markussen J, Havelund S, Kurtzhals Pet al. Soluble fatty acid acylated insulins bind to albumin and show protracted action in pigs.Diabetologia 1996; 39: 281–8.

    Article  PubMed  CAS  Google Scholar 

  50. Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix 25, a novel protamine based insulin lispro formulation. Humalog Mix 25 Study Group.Diabetes Care 1999; 22: 1258-61.58–1258-61.61.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Endocrinology and Genetics, Department of Pediatrics, All India Institute of Medical Sciences, Ansari Nagar, 110 029, New Delhi

    Balu Vaidyanathan & P. S. N. Menon (Additional Professor Pediatrics, Officer in-charge, Genetics unit)

Authors
  1. Balu Vaidyanathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. S. N. Menon
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vaidyanathan, B., Menon, P.S.N. Insulin analogues and management of diabetes mellitus. Indian J Pediatr 67, 435–441 (2000). https://doi.org/10.1007/BF02859462

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02859462

Key words

Search

Navigation